# Deciphering the Complexities of Sodium Voltage-Gated Channel Alpha Subunit 1 (SCN1A) Mutation: A Case of Intractable Epilepsy in a Five-and-a-Half-Month-Old Male

## TL;DR

This paper discusses a case of intractable epilepsy in an infant caused by a mutation in the SCN1A gene, highlighting the challenges in diagnosis and treatment.

## Contribution

The paper presents a clinical case emphasizing the role of genetic testing in managing SCN1A-related epilepsy.

## Key findings

- The infant's seizures were unresponsive to multiple antiepileptic drugs, indicating refractory epilepsy.
- Genetic testing confirmed a SCN1A mutation, linking it to developmental and epileptic encephalopathy.
- The case underscores the need for personalized treatment strategies in SCN1A-related epilepsy.

## Abstract

If the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene, which encodes Nav1.1 protein, undergoes pathological mutation, it results in a wide range of epileptic syndrome, including febrile seizure, genetic epilepsy with febrile seizure plus (GEFS+), and developmental and epileptic encephalopathy (DEE), including Dravet syndrome. We present the case of a five-and-a-half-month-old boy with SCN1A gene-related epileptic seizures, starting as focal seizures and progressing to generalized tonic-clonic seizures. Despite treating the seizures with multiple antiepileptic drugs, including phenytoin, sodium valproate, levetiracetam, perampanel, and clobazam, it was very difficult to control the seizures, and genetic testing was suggested. The SCN1A mutation leads to either loss of function, including GEFS+ and Dravet syndrome, or gain of function, including familial hemiplegic migraine type 3. The case emphasizes the importance of genetic testing in refractory epilepsy management to provide medical strategies for the diagnosis. It focuses on the difficulties faced in diagnostic and treatment strategies for the management of SCN1A-related epilepsy. It emphasizes the importance of monitoring and personalized treatment strategies to reduce the incidence of refractory epilepsy.